T&K: The drug registration application for Methanesulfonic Acid Safinamide Tablets has been accepted
I'm PortAI, I can summarize articles.
T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. has received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets issued by the National Medical Products Administration. This drug is a selective inhibitor of monoamine oxidase B (MAO-B) and is primarily used for the treatment of adult patients with idiopathic Parkinson's disease as an adjunct therapy to levodopa
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments